Regeneron to discontinue nesvacumab/Eylea combo
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it will discontinue development of a fixed combination therapy comprising nesvacumab (REGN910) plus Eylea aflibercept to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD) after the combination "did not provide sufficient differentiation" from Eylea monotherapy in two Phase II trials.
The Phase II RUBY and ONYX trials compared nesvacumab plus Eylea, formulated as a single intravitreal injection, to Eylea alone in patients with DME and patients with wet AMD, respectively. The primary endpoint of both trials assessed the change in best-corrected visual acuity (BCVA) between week 12 and 36 as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score. The trials examined bi-monthly and quarterly dosing of the combination...